Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other financing activities (2024)

Historic Other financing activities for Inhibikase Therapeutics (IKT) over the last 1 years, with Q1 2024 value amounting to -$30608.0.

  • Inhibikase Therapeutics' Other financing activities changed N/A to -$30608.0 in Q1 2024 from the same period last year, while for Mar 2025 it was -$30608.0, marking a year-over-year change of. This contributed to the annual value of -$138556.0 for FY2023, which is N/A changed from last year.
  • Per Inhibikase Therapeutics' latest filing, its Other financing activities stood at -$30608.0 for Q1 2024.
  • Over the past 5 years, Inhibikase Therapeutics' Other financing activities peaked at -$30608.0 during Q1 2024, and registered a low of -$30608.0 during Q1 2024.